ClinicalTrials.gg
TerminatedNCT02895100Updated Aug 21, 2025Results posted

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

A Phase 2 interventional study of PTG-100 and Placebo in Ulcerative Colitis, sponsored by Protagonist Therapeutics, Inc.. Terminated at 98 sites in 17 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Data Monitoring Committee discontinued the trial due to futility-based outcome

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 615 studies in Colitis, Ulcerative with a site in United States — 115 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
233rd of 499
98 · median 76
Started
2016
with 26 others
Phase 2
146 of 615
25 open now
Registered
264th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 233rd largest by enrollment of the 499 interventional ones that give a count, is one of 27 that started in 2016, is one of 146 in phase 2, and was the 264th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

115 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).

Read the detailed description

This is a Phase II multi-centre, double blind, randomised, placebo-controlled, clinical study to evaluate the efficacy, safety, and tolerability of an oral peptide, PTG-100, administered as capsules for 12 weeks in subjects with moderate to severe UC.

Following screening procedures and confirmation of subject eligibility, subjects will be randomised 1:1:1:1 to one of three daily doses of PTG-100 (150, 300 or 900 mg) or placebo. Stratification will be based on subjects' prior treatment with anti-TNF agents, with a maximum of 50% of subjects with prior unsuccessful anti-TNF agent treatments. Subjects will be treated with study drug for 12 weeks. Sigmoidoscopies will be performed at the Screening Visit and on Week 12. A final Follow Up Visit will occur on Week 16, when subject has been off study treatment for 4 weeks. Clinical, safety, pharmacokinetic (PK) and pharmacodynamic (PD) parameters will be evaluated on an ongoing basis during the 16 week study.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • ulcerative colitis
  • inflammatory bowel disease
  • PROPEL
  • Propel Study
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects age 18 to 80 years, inclusive
  • Diagnosis of UC for at least 2 months prior to screening
  • Moderate to severe active UC as defined by Mayo Score of 6 to 12 inclusive (range of 0-12) at baseline with endoscopy score of at least 2 (range 0-3)
  • Subject must have had an inadequate response, loss of response to or intolerance to at least of of the following medications: immunomodulators, TNF-alpha antagonists or
  • Subject is unlikely to conceive, as defined by one of the following: a) subject is male, b) subject is surgically sterilized female, c) subject is female >= 45 years of age with clinical documentation of menopause, or d) subject is woman of child bearing potential () and agrees to abstain from heterosexual activity, use adequate hormonal or use double barrier contraception.
  • For WOCBP, a negative pregnancy test at screening and within 24 hours of first dose of study medication

Exclusion criteria

Exclusion Criteria include:

  • Subject has Crohn's Disease (CD), indeterminate colitis (IC) or presence or history of fistula with CD
  • History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma; history or is at imminent risk of colectomy
  • History or current evidence of colonic dysplasia or adenomatous colonic polyps
  • Current bacterial or parasitic pathogenic enteric infection, including Clostridium difficile, infection with or C virus, infection with , infection requiring hospitalisation or intravenous antimicrobial therapy, or opportunistic infection within 6 months, any infection requiring antimicrobial therapy within 2 weeks, history of more than one episode of herpes zoster or any episode of disseminated zoster
  • within one month prior to screening
  • Subject has a concurrent , unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results or poses additional risk to the subject
  • Known primary or secondary immunodeficiency
  • History of myocardial infarction, unstable angina, , decompensated heart failure requiring hospitalisation, congestive heart failure ( Class 3 or 4), uncontrolled arrhythmias, cardiac revascularisation, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening
  • Clinically meaningful laboratory abnormalities at screening
  • Pregnant or lactating females
  • Any surgical procedure requiring general anaesthesia within one month prior to screening, or planned elective surgery during the study
  • History of malignant neoplasms or carcinoma in situ within 5 years prior to screening
  • History of any major neurological disorders, as judged by the Investigator, or positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist
  • Current or recent history of alcohol dependence or illicit drug use within 1 year prior to screening.
  • Subject is mentally or legally incapacitated at the time of screening visit or has a history of clinically significant psychiatric disorders that would impact the subject's ability to participate in the trial according to the investigator
  • Unable to attend study visits or comply with procedures
  • Concurrent participation in any other interventional study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    PTG-100 (150 mg QD)

    Low dose

    Drug: PTG-100

  • Experimental
    PTG-100 (300 mg QD)

    Medium dose

    Drug: PTG-100

  • Experimental
    PTG-100 (900 mg QD)

    High dose

    Drug: PTG-100

  • Placebo comparator
    Placebo group

    Placebo control

    Drug: Placebo

Interventions

  • DrugPTG-100

    Daily dosing of PTG-100 by subject for a 12 week treatment period.

  • DrugPlacebo

    Daily dosing of Placebo capsules by subject for a 12 week treatment period.

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo

    The primary efficacy endpoint for this study was the proportion of subjects receiving PTG-100 with clinical remission at Week 12. Clinical remission was defined using the Mayo subscores of stool frequency, rectal bleeding, and endoscopy.

    Time frame: 12 week treatment period

07

Results

Posted Mar 22, 2021

Participant flow

Participant flow — Overall Study
MilestonePTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo Group
Started25252325
Completed14141515
Not completed1111810

Outcome measures

PrimaryProportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo

The primary efficacy endpoint for this study was the proportion of subjects receiving PTG-100 with clinical remission at Week 12. Clinical remission was defined using the Mayo subscores of stool frequency, rectal bleeding, and endoscopy.

Time frame:
12 week treatment period
Reported as:
Count of participants · Participants
Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo
ParticipantsPTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo Group
Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo1234

Adverse events

Collected over Day 0 to Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PTG-100 (150 mg QD)0/25 (0%)2/25 (8%)7/25 (28%)
PTG-100 (300 mg QD)0/25 (0%)2/25 (8%)11/25 (44%)
PTG-100 (900 mg QD)0/23 (0%)1/23 (4.3%)14/23 (60.9%)
Placebo Group0/25 (0%)1/25 (4%)11/25 (44%)
Most frequent serious events
Most frequent serious events
EventPTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo Group
Colitis UlcerativeGastrointestinal disorders0/250/251/230/25
Perirectal AbscessInfections and infestations1/250/250/230/25
Ulcerative Colitis FlareGastrointestinal disorders1/250/250/230/25
PregnancyPregnancy, puerperium and perinatal conditions0/251/250/230/25
Intestinal ischemiaGastrointestinal disorders0/250/250/231/25
Exacerbation of Ulcerative ColitisGastrointestinal disorders0/251/250/230/25
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo Group
HeadacheNervous system disorders0/250/254/232/25
Colitis UlcerativeGastrointestinal disorders3/252/253/230/25
NasopharyngitisInfections and infestations0/253/250/231/25
FatigueGeneral disorders0/250/252/231/25
ArthralgiaMusculoskeletal and connective tissue disorders0/250/252/230/25
Abdominal PainGastrointestinal disorders0/252/250/230/25
AnemiaBlood and lymphatic system disorders0/252/251/231/25
ArthritisMusculoskeletal and connective tissue disorders0/252/250/230/25
Articular Disc DisorderMusculoskeletal and connective tissue disorders0/250/251/230/25
Back PainGeneral disorders0/250/251/230/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)PTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo GroupTotal
Mean45.2 ± 13.843.8 ± 1740.6 ± 14.142.2 ± 14.943 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)PTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo GroupTotal
Female715141046
Male181091552
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo GroupTotal
Race — White1923222387
Race — Asian41005
Race — Black or African American20125
Race — other01001
Weight
Weight(kg)PTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo GroupTotal
Mean77.8 ± 16.370.7 ± 15.472.3 ± 19.169.5 ± 16.172.5 ± 16.7
Height
Height(cm)PTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo GroupTotal
Mean173.2 ± 7.3169.8 ± 9.7173.0 ± 9.1171.1 ± 8.3171.7 ± 8.6
BMI
BMI(kg/m^2)PTG-100 (150 mg QD)PTG-100 (300 mg QD)PTG-100 (900 mg QD)Placebo GroupTotal
Mean25.7 ± 4.724.5 ± 5.223.9 ± 4.523.7 ± 4.724.5 ± 4.8
08

Study locations

98 sites
  • Site Reference ID/Investigator # 101
    Los Angeles, California 90036, United States
  • Site Reference ID/Investigator # 102
    Los Angeles, California 90036, United States
  • Site Reference ID/Investigator # 125
    Colorado Springs, Colorado 80907, United States
  • Site Reference ID/Investigator # 120
    Miami, Florida 33126, United States
  • Site Reference ID/Investigator # 106
    Port Orange, Florida 32128, United States
  • Site Reference ID/Investigator # 115
    Saint Augustine, Florida 32086, United States
  • Site Reference ID/Investigator # 116
    Sweetwater, Florida 33172, United States
  • Site Reference ID/Investigator # 100
    Atlanta, Georgia 30607, United States
  • Site Reference ID/Investigator # 104
    Marietta, Georgia 30060, United States
  • Site Reference ID/Investigator # 112
    Suwanee, Georgia 30024, United States
  • Site Reference ID/Investigator # 107
    Chicago, Illinois 60611, United States
  • Site Reference ID/Investigator # 126
    Bastrop, Louisiana 71220, United States
  • Site Reference ID/Investigator # 114
    Shreveport, Louisiana 71105, United States
  • Site Reference ID/Investigator # 117
    Chevy Chase, Maryland 20815, United States
  • Site Reference ID/Investigator # 109
    Great Neck, New York 11021, United States
  • Site Reference ID/Investigator # 122
    New York, New York 10065, United States
  • Site Reference ID/Investigator # 119
    Cincinnati, Ohio 45219, United States
  • Site Reference ID/Investigator # 110
    Hermitage, Tennessee 37076, United States
  • Site Reference ID/Investigator # 128
    Nashville, Tennessee 37212, United States
  • Site Reference ID/Investigator # 118
    DeSoto, Texas 75035, United States
  • Site Reference ID/Investigator # 113
    Richmond, Virginia 23249, United States
  • Site Reference ID/Investigator # 901
    Murdoch, Western Australia 6150, Australia
  • Site Reference ID/Investigator # 908
    Herston, 4006, Australia
  • Site Reference ID/Investigator # 900
    South Brisbane, 4101, Australia
  • Site Reference ID/Investigator # 907
    Subiaco, 6008, Australia
  • Site Reference ID/Investigator # 559
    Ghent, 9000, Belgium
  • Site Reference ID/Investigator # 533
    Kortrijk, 8500, Belgium
  • Site Reference ID/Investigator # 505
    Leuven, 3000, Belgium
  • Site Reference ID/Investigator # 573
    Mostar, 88000, Bosnia and Herzegovina
  • Site Reference ID/Investigator # 571
    Tuzla, 3 75000, Bosnia and Herzegovina
  • Site Reference ID/Investigator # 103
    Vancouver, British Columbia V6Z 2K5, Canada
  • Site Reference ID/Investigator # 105
    London, Ontario N6A 5A5, Canada
  • Site Reference ID/Investigator #556
    Osijek, 31000, Croatia
  • Site Reference ID/Investigator # 550
    Split, 17 21000, Croatia
  • Site Reference ID/Investigator # 562
    Zagreb, 21 10000, Croatia
  • Site Reference ID/Investigator # 517
    Nový Hradec Králové, 500 12, Czechia
  • Site Reference ID/Investigator # 539
    Zlín, 76275, Czechia
  • Site Reference ID/Investigator # 560
    Berlin, 13353, Germany
  • Site Reference ID/Investigator # 542
    Berlin, 14050, Germany
  • Site Reference ID/Investigator # 532
    Kiel, 24105, Germany
  • Site Reference ID/Investigator # 506
    Leipzig, 4103, Germany
  • Site Reference ID/Investigator # 572
    Mannheim, 68167, Germany
  • Site Reference ID/Investigator # 538
    Münster, 48149, Germany
  • Site Reference ID/Investigator # 574
    Tübingen, 72076, Germany
  • Site Reference ID/Investigator # 541
    Ulm, 89073, Germany
  • Site Reference ID/Investigator # 554
    Budapest, 1036, Hungary
  • Site Reference ID/Investigator # 558
    Budapest, 1125, Hungary
  • Site Reference ID/Investigator # 552
    Debrecen, 4032, Hungary
  • Site Reference ID/Investigator # 567
    Eger, 3300, Hungary
  • Site Reference ID/Investigator # 557
    Kistarcsa, 2143, Hungary
  • Site Reference ID/Investigator # 544
    Mosonmagyaróvár, 9200, Hungary
  • Site Reference ID/Investigator # 563
    Sopron, 9400, Hungary
  • Site Reference ID/Investigator # 501
    Riga, 1002, Latvia
  • Site Reference ID/Investigator # 545
    Riga, LV-1002, Latvia
  • Site Reference ID/Investigator # 568
    Amsterdam, 1105, Netherlands
  • Site Reference ID/Investigator # 903
    Dunedin, 9016, New Zealand
  • Site Reference ID/Investigator # 902
    Newton, 6021, New Zealand
  • Site Reference ID/Investigator # 529
    Kielce, 25-364, Poland
  • Site Reference ID/Investigator # 576
    Krakow, 31-530, Poland
  • Site Reference ID/Investigator # 540
    Krakow, 31-531, Poland
  • Site Reference ID/Investigator # 512
    Ksawerów, 95-054, Poland
  • Site Reference ID/Investigator # 530
    Lodz, 90-153, Poland
  • Site Reference ID/Investigator # 518
    Lodz, 90-302, Poland
  • Site Reference ID/Investigator # 577
    Poznan, 61-845, Poland
  • Site Reference ID/Investigator # 546
    Sopot, 81-756, Poland
  • Site Reference ID/Investigator # 513
    Warsaw, 00-632, Poland
  • Site Reference ID/Investigator # 531
    Włocławek, 87-806, Poland
  • Site Reference ID/Investigator # 553
    Kazan', 420029, Russia
  • Site Reference ID/Investigator # 524
    Moscow, 125412, Russia
  • Site Reference ID/Investigator # 536
    Moskva, 127015, Russia
  • Site Reference ID/Investigator # 515
    Novosibirsk, 630117, Russia
  • Site Reference ID/Investigator # 526
    Rostov-on-Don, 344022, Russia
  • Site Reference ID/Investigator # 514
    Saint Petersburg, 191186, Russia
  • Site Reference ID/Investigator # 522
    Saint Petersburg, 195067, Russia
  • Site Reference ID/Investigator # 555
    Saint Petersburg, 195257, Russia
  • Site Reference ID/Investigator # 523
    Samara, 443093, Russia
  • Site Reference ID/Investigator # 551
    Ufa, 450071, Russia
  • Site Reference ID/Investigator # 525
    Yaroslavl, 150000, Russia
  • Site Reference ID/Investigator # 521
    Belgrade, 0 11080, Serbia
  • Site Reference ID/Investigator # 575
    Belgrade, 11000, Serbia
  • Site Reference ID/Investigator # 566
    Belgrade, 11080, Serbia
  • Site Reference ID/Investigator # 500
    Kragujevac, 12 34111, Serbia
  • Site Reference ID/Investigator # 543
    Niš, 18105, Serbia
  • Site Reference ID/Investigator # 502
    Zvezdara, 0 11050, Serbia
  • Site Reference ID/Investigator # 906
    Daegu, 42415, South Korea
  • Site Reference ID/Investigator # 905
    Seoul, 06591, South Korea
  • Site Reference ID/Investigator # 904
    Seoul, 3722, South Korea
  • Site Reference ID/Investigator # 510
    Chernivtsi, 3110, Ukraine
  • Site Reference ID/Investigator # 535
    Ivano-Frankivsk, 76018, Ukraine
  • Site Reference ID/Investigator # 509
    Kharkiv, 6100, Ukraine
  • Site Reference ID/Investigator # 508
    Kharkiv, 61039, Ukraine
  • Site Reference ID/Investigator # 549
    Kiev, Ukraine
  • Site Reference ID/Investigator # 565
    Kyiv, 2232, Ukraine
  • Site Reference ID/Investigator # 534
    Lviv, 79059, Ukraine
  • Site Reference ID/Investigator # 520
    Odesa, 65025, Ukraine
  • Site Reference ID/Investigator # 504
    Uzhhorod, 88000, Ukraine
  • Site Reference ID/Investigator # 507
    Vinnytsia, 21018, Ukraine
  • Site Reference ID/Investigator # 547
    Zaporizhzhya, 609065, Ukraine
09

References and documents

Publications

  • Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R, Kanwar B, Shames R, D'Haens G, Schreiber S, Danese S, Feagan B, Pai RK, Liu DY, Gupta S. PTG-100, an Oral alpha4beta7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology. 2021 Dec;161(6):1853-1864.e10. doi: 10.1053/j.gastro.2021.08.045. Epub 2021 Aug 30. PubMed 34474038 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Mar 2018 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 2 years 11 months after primary completion. A results delay was requested in Feb 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2016
First posted
Sep 9, 2016
Start
Dec 2016
Primary completionActual
Mar 26, 2018
CompletionActual
Mar 26, 2018
Results delay requested
Feb 28, 2019
Results first posted
Mar 22, 2021
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02895100
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 9, 2016
Start date
Dec 2016
Primary completion
Mar 26, 2018
Completion
Mar 26, 2018
Results posted
Mar 22, 2021
Last update
Aug 21, 2025

Study contacts

Director Clinical Development
study director · Protagonist Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion